Healthpeak Properties Inc (NYSE: DOC) Seen Running Too Hot, Let’s Look At This More Closely

Currently, there are 699.49M common shares owned by the public and among those 696.13M shares have been available to trade.

The company’s stock has a 5-day price change of -0.69% and -0.30% over the past three months. DOC shares are trading -1.23% year to date (YTD), with the 12-month market performance up to 8.64% higher. It has a 12-month low price of $17.49 and touched a high of $23.13 over the same period. DOC has an average intraday trading volume of 4.76 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.41%, -1.00%, and -4.62% respectively.

Institutional ownership of Healthpeak Properties Inc (NYSE: DOC) shares accounts for 94.65% of the company’s 699.49M shares outstanding.

It has a market capitalization of $14.27B and a beta (3y monthly) value of 1.00. The stock’s trailing 12-month PE ratio is 57.69, while the earnings-per-share (ttm) stands at $0.35. The company has a PEG of 31.70 and the debt-to-equity ratio at 1.10. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.05% over the week and 2.20% over the month.

Earnings per share for the fiscal year are expected to decrease by -38.64%, and 31.64% over the next financial year. EPS should shrink at an annualized rate of 1.82% over the next five years, compared to 52.84% over the past 5-year period.

Looking at the support for the DOC, a number of firms have released research notes about the stock. Morgan Stanley stated their Overweight rating for the stock in a research note on January 15, 2025, with the firm’s price target at $25. Deutsche Bank coverage for the Healthpeak Properties Inc (DOC) stock in a research note released on October 21, 2024 offered a Buy rating with a price target of $28. Wedbush was of a view on May 03, 2024 that the stock is Outperform, while Exane BNP Paribas gave the stock Outperform rating on April 26, 2024, issuing a price target of $19- $21. Mizuho on their part issued Buy rating on April 22, 2024.

Most Popular

Related Posts